ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2310

The Predictive Risk Factors for Complication of Infection during the Treatment for Inflammatory Myopathies Complicated with Interstitial Lung Disease

Yumiko SUGIYAMA1,2, Maasa Tamura1,2,3, Ryusuke Yoshimi1,2, Naoki Hamada1,2, Hideto Nagai1,2, Yuko Tatekabe1,2, Naomi Tsuchida2,4, Yutaro Soejima1,2, Yosuke Kunishita2,4, Daiga Kishimoto1,2, Hiroto Nakano1,2, Reikou Kamiyama1,2, Kaoru Minegishi2,5, Yukiko Asami1,2, Yohei Kirino2,4, Shigeru Ohno2,5 and Hideaki Nakajima1, 1Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, 2Y-CURD Study Group, Yokohama, Japan, 3Nagaoka Red Cross Hospital, Nagaoka, Japan, 4Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan, 5Center for Rheumatic Disease, Yokohama City University Medical Center, Yokohama, Japan

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Infection, interstitial lung disease, polymyositis/dermatomyositis (PM/DM) and prognostic factors

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Muscle Biology, Myositis and Myopathies - Poster II: Clinical

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:  Interstitial lung disease (ILD) is one of the predominant causes of death in polymyositis/dermatomyositis (PM/DM). We have already reported that low PaCO2 and interstitial lesions in more cranial zone of lungs are independent prognostic factors for ILD associated with PM/DM (PM/DM-ILD), and the most common causes of death in early stage are respiratory failure and infection. Here we investigated the predictive factors for complication of infection during treatment for PM/DM-ILD.

Methods:  We retrospectively analyzed clinical features, laboratory and high-resolution computed tomography (HRCT) findings at baseline, initial therapeutic regimens, clinical outcomes, and episode of serious infection of patients with PM/DM-ILD who had received initial treatment at the two hospitals belonging to Yokohama City University from 1993 to 2015. The lungs were horizontally divided into 4 zones (Zone A to D from more cranial area) in HRCT, and severity of ILD lesions were evaluated in each zone. We conducted univariate and multivariate analyses to extract risk factors for death and infection.  

Results: One hundred six patients (PM 19, DM 49, clinically amyopathic DM (CADM) 38) were recruited. The mean age was 55 +/- 14 years, and 77 (73%) were female. As initial therapies, oral prednisolone (PSL) was prescribed in all patients. Methylprednisolone (mPSL) pulse, intravenous cyclophosphamide (IVCY), and oral calcineurin inhibitor therapies were performed in 77 (73%), 43 (41%) and 73 (69%), respectively. Thirty-seven (35%) received combination therapy with IVCY and a calcineurin inhibitor. Forty patients (38%) had a total of 54 events of serious infection at 40 +/- 26 days from initiation of immunosuppressants. The foci of infection were seen most commonly in lung (bacterial pneumonia 19, pulmonary suppuration 2, pneumocystis pneumonia 9, CMV infection 15, and the others 9). Lower serum albumin level (p = 0.01), higher serum CRP, LDH, KL-6 levels (p = 0.01, p = 0.001, p = 0.01, respectively), high initial dose of PSL (p = 0.01), mPSL pulse (p = 0.02), IVCY (p < 0.001), and combined immunosuppressants (p = 0.04) were extracted as risk factors for infection by univariate analyses (Table 1). There was no significant relation between severity of ILD and infection. A multivariate logistic regression analyses revealed that the high initial dosage of PSL (p = 0.003, hazard ratio 6.21) and higher serum LDH level (p = 0.017, hazard ratio 4.08) were independent risk factors for infection. Of 11 patients, who died within 6 months, four (36%) were died of infection.

Conclusion: Although rapid and intensive therapies are required for PM/DM-associated ILD, appropriate monitoring, prophylaxis and early treatment for infection are important, especially in patients who received high-dose of initial glucocorticoid and showed higher serum LDH level.


Disclosure: Y. SUGIYAMA, None; M. Tamura, None; R. Yoshimi, None; N. Hamada, None; H. Nagai, None; Y. Tatekabe, None; N. Tsuchida, None; Y. Soejima, None; Y. Kunishita, None; D. Kishimoto, None; H. Nakano, None; R. Kamiyama, None; K. Minegishi, None; Y. Asami, None; Y. Kirino, None; S. Ohno, None; H. Nakajima, None.

To cite this abstract in AMA style:

SUGIYAMA Y, Tamura M, Yoshimi R, Hamada N, Nagai H, Tatekabe Y, Tsuchida N, Soejima Y, Kunishita Y, Kishimoto D, Nakano H, Kamiyama R, Minegishi K, Asami Y, Kirino Y, Ohno S, Nakajima H. The Predictive Risk Factors for Complication of Infection during the Treatment for Inflammatory Myopathies Complicated with Interstitial Lung Disease [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/the-predictive-risk-factors-for-complication-of-infection-during-the-treatment-for-inflammatory-myopathies-complicated-with-interstitial-lung-disease/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-predictive-risk-factors-for-complication-of-infection-during-the-treatment-for-inflammatory-myopathies-complicated-with-interstitial-lung-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology